Does Tirzepatide Increase Testosterone Levels?

You've lost weight on tirzepatide and your testosterone reading has shifted — here's why

Imagine you're a few months into treatment, you've had a blood test, and your testosterone level is higher than it was before you started. Your first instinct might be to credit tirzepatide directly. In reality, what you're most likely seeing is the downstream effect of losing a significant amount of body fat.

Adipose tissue is hormonally active. In men particularly, excess body fat raises the activity of an enzyme called aromatase, which converts testosterone into oestrogen. The more fat tissue, the more of that conversion takes place, and the lower free testosterone tends to sit. Studies in men with obesity have consistently shown that meaningful weight loss, by any method, is followed by a rise in total and free testosterone. The question is whether tirzepatide adds anything beyond that weight-loss effect, and current evidence does not establish that it does. The improvement tracks with how much weight is lost, not with which treatment produced the loss.

A question our prescribers hear most weeks is whether starting tirzepatide will help with low testosterone specifically. The honest answer is: not as a direct pharmacological effect. But if obesity is suppressing your testosterone, and tirzepatide helps you lose a substantial amount of weight, your levels may well improve as a consequence. That is worth knowing, but it is also worth framing correctly so you go in with realistic expectations.

For further context on how tirzepatide works as a medicine, the Mounjaro overview page covers its dual GIP and GLP-1 mechanism in plain terms.

What happens to testosterone when fat mass falls — the biology behind the observation

Tirzepatide works by activating two gut-hormone receptors, slowing gastric emptying and reducing appetite. In the SURMOUNT-1 trial, participants lost an average of around 20% of their body weight over 72 weeks at the highest dose, as published in the New England Journal of Medicine. That scale of fat-mass reduction is not trivial from an endocrine perspective.

When fat mass falls, aromatase activity drops with it. Less peripheral conversion means more testosterone remains in circulation. Sex hormone-binding globulin also tends to decline with obesity and can recover as weight normalises, which affects how much testosterone is biologically available. The result, in many men who lose significant weight, is a testosterone reading that looks meaningfully better on paper and may be felt in terms of energy, mood and libido.

It is important to be precise about what this is and is not. It is a metabolic correction, not a pharmacological testosterone boost. Tirzepatide does not bind to androgen receptors, does not stimulate Leydig cells in the testes, and is not a treatment for hypogonadism. Men with clinical hypogonadism (low testosterone from primary or secondary causes unrelated to obesity) would still need specific assessment and, where appropriate, treatment for that condition in parallel.

The relationship between tirzepatide and insulin follows a similar logic: the medicine's metabolic effects ripple outward in ways that are not always obvious from its mechanism alone.

The picture in women, particularly those with PCOS

The conversation about tirzepatide and testosterone in women is different, and largely centres on polycystic ovary syndrome. PCOS is characterised in part by elevated androgens including testosterone, and obesity tends to worsen androgen excess because it worsens insulin resistance, which in turn drives the ovaries to produce more testosterone.

GLP-1 receptor agonists have been studied in women with PCOS, with early data suggesting that improving insulin sensitivity and reducing weight can lower free androgen levels and improve menstrual regularity. Tirzepatide's dual action on both GLP-1 and GIP receptors makes it a candidate for further research in this area, but as of mid-2026 there are no large, dedicated tirzepatide-PCOS trials with testosterone as a primary endpoint. Current findings are preliminary and cannot be taken as a treatment indication for PCOS or androgen excess.

For women in this situation, the right conversation is with a prescriber who knows your full hormonal history. Tirzepatide is licensed for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related condition, and that clinical assessment is where eligibility is established. If you want to understand the dose journey, the 5mg Mounjaro dose page covers what early titration looks like in practice.

The NHS medicine page for tirzepatide is a reliable starting point for factual information on its licensed uses and known effects.

What this means practically if testosterone is part of your health picture

If you are considering tirzepatide and testosterone is a concern, whether yours is lower than it should be or, in the context of PCOS, higher than it should be, the first step is an honest conversation with a clinician rather than self-directed research alone.

Weight loss achieved through a clinically supervised programme is likely to have metabolic benefits that extend well beyond the number on the scales. Hormone balance is one of them. But expecting tirzepatide to act as a testosterone therapy in its own right would be setting the wrong target. The medicine's licensed purpose is weight management, and any hormonal improvements are secondary to that.

Dose progression is also relevant here: the metabolic impact of tirzepatide grows as the dose increases toward the maintenance level, and if you are wondering when and how that happens, the guidance on how to increase your tirzepatide dose explains the titration process in practical terms. Understanding whether dose increases translate to greater weight loss gives useful context for what to expect over the course of treatment. For anyone considering costs alongside clinical decisions, the Mounjaro pricing page sets out what private treatment involves. Suitability, as always, is determined through clinical review. Check your eligibility and speak to the prescribers at the nume consultation page.